I asked a friend to send me a pdf of this article. When (if) I get it i'll post and you can send me an email and i'll reply with the article.
I have no idea. Maybe an institution got fed up with the anemic tali sales and decided to cut their losses. I am considering doing the same thing.
I think you are right messina. Catalyst is down 22%. AF can really move the market. Firdapse is such small beans for BMRN. I really wish they would unload the entire program and focus on 673, 701, Batten's etc. I realize firdapse brings in revenue but is it really worth the bad press it is generating?
There is definitely a difference. Anchor has the added layer of complexity of the statin. One way to resolve a controversy is to generate more data.
I am sort of baffled as to why they are using mineral oil instead of saline or water. I guess they are afraid the study subjects are going to find out which group they are in and that would bias the blinding.
ok. i see on page 11 of the briefing the comments about Lovaza. An analyst commented that the MO issue was debated prior to marine approval.
Heck, if FDA is really worried about the mineral oil issue they should terminate Reduce-It as it is also controlled with mineral oil. 4,000 people in the control group will be exposed to a slightly higher risk of a CV event.
Rosenman comments in his Oct 14 SA piece that "Lovaza saw similar signals in their trial which did not include mineral oil,"
But page 55 (bottom half) of the briefing document indicates that "The placebo groups in COMBOS and FIRST had small reductions from baseline in TG at the 8 week and 13 week time points (-6.3% and -2.0%, respectively). The placebo-treated patients in COMBOS also had reductions in other measured lipid
parameters. These results suggest the changes in ANCHOR are atypical, but the etiology
of this remains unclear.
Am I missing something? Or is Rosenman missing something?
Quoth the Raven forgot to mention that all bios are getting crushed this week. BCRX, EXEL, BMRN and many others are ll down big. BMRN is raising a lot of money at least.
Anyone care to explain how senior subordinated notes work? How do the capped calls work? What does the following (below) from the press release mean?
"These activities could have the effect of increasing, or reducing the size of any decrease in, the price of the relevant Notes and/or BioMarin's common stock concurrently with, or shortly after, the pricing of the relevant Notes."
It seems to me that a purchaser of the notes will resist a buyout below $94.15. Is this correct?